Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMIST trial of minimally invasive surfactant therapy in preterm infants with neonatal respiratory distress syndrome
ACTRN12611000917932Phase 4Not yet recruiting
- Sponsor
- Menzies Institute for Medical Research
- Start
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Menzies Institute for Medical Research. Primary endpoint: Duration of respiratory support. Planned start Jan 2017; status: not yet recruiting.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on ACTRN12611000917932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000917932.